arcoris bio, a Swiss life science research tools and in vitro diagnostics company, has secured CHF 6.3 million in a seed financing round. The investment enables the Schlieren-based start-up to accelerate industrialization of its biomarker detection platform, expand of strategic partnerships, and launch new products..

瑞士生命科学研究工具和体外诊断公司arcoris bio在种子轮融资中获得了630万瑞士法郎。这笔投资使这家位于施利伦的初创公司能够加速其生物标志物检测平台的工业化进程，拓展战略合作伙伴关系，并推出新产品。

arcoris bio

虹之生物

develops next-generation technologies for biomarker detection in research and diagnostics. MUSE, arcoris bio’s nanotechnology platform for biomarker detection and signal amplification, enables simultaneous detection of multiple biomarkers with unprecedented ease and sensitivity. By allowing the measurement of several difficult-to-detect biomarkers within a single sample at higher throughput, MUSE is poised to play a pivotal role in the evolution of digital pathology..

开发用于研究和诊断的下一代生物标志物检测技术。MUSE是arcoris bio公司用于生物标志物检测和信号放大的纳米技术平台，能够以前所未有的便捷性和灵敏度同时检测多种生物标志物。通过在单个样本中以更高通量测量多个难以检测的生物标志物，MUSE将在数字病理学的发展中发挥关键作用。

The company has closed an oversubscribed seed funding round co-led by

公司已经完成了一轮超额认购的种子轮融资，由以下机构共同领投：

Ventura Ace

文图拉·艾斯

and

和

ZEISS Ventures

蔡司创投

, with participation from Zürcher Kantonalbank (

，苏黎世州银行（Zürcher Kantonalbank）参与其中，

ZKB

ZKB

) and both existing and new private investors. “Attracting two lead investors with deep industry expertise is a strong validation of our technical and business strategy. This support empowers us in our mission of transforming biomarker detection and digital pathology,” commented Simon Restrepo, Co-founder and CSO arcoris bio..

）以及现有的和新的私人投资者。“吸引两位具有深厚行业专业知识的领投投资者，是对我们的技术和商业战略的有力验证。这一支持使我们能够在转化生物标志物检测和数字病理学的使命中更有力量，”Arcoris Bio的联合创始人兼首席科学官西蒙·雷斯特雷波评论道。

The company was founded by MUSE inventors Simon Restrepo and Scott E. Fraser, together with entrepreneur H. Kaspar Binz, and is headquartered in Schlieren, Switzerland. Matyas Vegh serves as CEO. The serial entrepreneur was previously CEO of Creoptix and The Genetics Company, as well as Chief Commercial Officer at Cytosurge..

该公司由 MUSE 发明者西蒙·雷斯特雷波（Simon Restrepo）和斯科特·E·弗雷泽（Scott E. Fraser）以及企业家 H. 卡斯帕·宾兹（H. Kaspar Binz）共同创立，总部位于瑞士施利伦。马蒂亚斯·韦格（Matyas Vegh）担任首席执行官。这位连续创业者曾担任 Creoptix 和 The Genetics Company 的首席执行官，以及 Cytosurge 的首席商务官。

Matyas Vegh, CEO arcoris bio, added: “Securing this financing marks a major milestone for arcoris bio. In a challenging market, we are grateful for the trust our investors have placed in our vision. Their support empowers us to bring our innovations to market faster, strengthen our operations, and scale to meet growing industry demand.”.

马蒂亚斯·韦格，arcoris bio首席执行官补充道：“确保此次融资标志着arcoris bio的一个重要里程碑。在充满挑战的市场中，我们感谢投资者对我们愿景的信任。他们的支持使我们能够更快地将创新成果推向市场，加强我们的运营能力，并扩大规模以满足不断增长的行业需求。”

Andreas Jenne, Investment Director at Ventura Ace, said: “We have been impressed by the arcoris bio team’s vision and early traction with industry partners. We believe MUSE represents a truly enabling technology for digital pathology.”

安德烈亚斯·詹恩，文图拉艾斯公司的投资总监表示：“我们对arcoris bio团队的愿景以及与行业合作伙伴的早期合作成果印象深刻。我们相信MUSE代表了一项真正能够推动数字病理学发展的技术。”

“arcoris bio’s MUSE technology fills a critical gap in the market to enable better diagnostics and applications like drug discovery or precision medicine. Its universal applicability is particularly exciting – MUSE acts like a molecular GPU, amplifying the capabilities of existing biomarker platforms and opening new paths for innovation,” highlighted Benedikt Klaes, Senior Investment Manager at ZEISS Ventures..

“arcoris bio的MUSE技术填补了市场上的一个关键空白，能够实现更好的诊断以及药物发现或精准医疗等应用。其普适性尤其令人兴奋——MUSE就像一个分子GPU，增强了现有生物标志物平台的能力，并为创新开辟了新途径，”蔡司风险投资公司的高级投资经理贝内迪克特·克莱斯强调道。

(Press release / SK)

（新闻稿 / SK）

Picture: human tonsils, FFPE section, 3-plex with commercially available antibodies / arcoris bio

图片：人类扁桃体，FFPE切片，使用商业抗体的3重染色 / arcoris bio

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送